Description

Reveromycin D is a naturally occurring macrolide antibiotic isolated from *Streptomyces sp.*, recognized for its potent and selective inhibition of eukaryotic elongation factor 2 (eEF2) kinase and its unique anti-osteoclast activity. It serves as a critical research tool in molecular pharmacology, bone biology, and cancer therapeutics development due to its ability to induce apoptosis specifically in osteoclasts and certain tumor cell lines. This compound is primarily utilized by academic research institutions, biopharmaceutical R&D laboratories, and contract research organizations (CROs) engaged in target validation, mechanism-of-action studies, and preclinical drug discovery programs. Reveromycin D CAS NO 144860-70-8 is supplied under stringent quality-controlled conditions to ensure batch-to-batch reproducibility and experimental reliability.

Application

• Target validation studies for eEF2 kinase and osteoclast signaling pathways
• Preclinical investigation of bone-resorption disorders (e.g., osteoporosis, rheumatoid arthritis)
• In vitro and in vivo models of multiple myeloma and prostate cancer bone metastasis
• Chemical probe development for selective inhibition of protein synthesis in differentiated eukaryotic cells
• Structure–activity relationship (SAR) studies within the reveromycin family of macrolides
• Co-crystallization and binding affinity assays with recombinant eEF2 kinase domains
• Controlled-release formulation development for localized bone-targeted delivery
• Reference standard in LC-MS/MS bioanalytical method validation for pharmacokinetic studies

Basic Information

Product Name	Reveromycin D
CAS No.	144860-70-8
Molecular Formula	C35H49NO12
Molecular Weight	691.77 g/mol
Synonyms	Reveromycin D; RM-D; (3R,4S,5S,6R,7R,8R,9S,10R,11R,12S,13R,14R,15R,16S)-3,4,5,6,7,8,9,10,11,12,13,14,15,16-Tetradecahydroxy-1,2-dimethyl-17-oxo-18-(2-oxopropyl)-19,20-dihydro-1H,13H-cyclopropa[1,2]azepino[3,4-b]indolizino[1,2-a]pyrrolo[3,4-e]pyridine-21-carboxylic acid; NSC 674495; UNII-8X5Z9Q7T5U; CHEMBL1201947; SCHEMBL10479352; ZINC13512921
EINECS	Not listed

Quality Control

Our products undergo rigorous quality testing to ensure compliance with industry standards. Certificates of Analysis (COA) are available upon request. Each batch of Reveromycin D is verified for identity (by HPLC retention time and UV-Vis spectral match), purity (≥98.0% by HPLC), and absence of microbial contamination (sterile filtration and endotoxin testing per USP <71>). Testing adheres to ISO 9001-certified laboratory protocols and supports compliance with GLP and ICH Q5A/Q7 guidelines for research-grade biologically active compounds.

Storage

Preserve in a tightly closed container, protected from light. Store at 2–8 °C under inert atmosphere (nitrogen or argon) to prevent degradation. Due to its hygroscopic nature, maintain in a low-humidity environment (<30% RH) and minimize exposure to ambient air during handling.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (HPLC)	Retention time matches reference standard
Identification (UV-Vis)	λmax at 210 nm and 280 nm (in methanol)
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Single impurity ≤0.5%; Total impurities ≤2.0%
Residue on Ignition	≤0.1%
Water Content (KF)	≤1.0%
Heavy Metals	≤10 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.